833 abstracts found.



Results filter

Introduction: Expanding the druggable genome

Year:

Session type:

Martin Drysdale
The Beatson Institute for Cancer Research, Glasgow, UK

Metastasis seeds and niches

Year:

Session type:

Joan Massagué
Memorial Sloan-Kettering Cancer Center, New York, USA

Enriching chemical space to drug undruggable targets

Year:

Session type:

David Spring
University of Cambridge, UK

Title TBC

Year:

Session type:

Neal Rosen
Memorial Sloan-Kettering Cancer Center, New York, USA

Drugging the undruggable: Small-molecule inhibition of Ras oncoprotein I

Year:

Session type:

Guowei Fang
Genentech/Roche, California, USA

Cancer Research UK Lifetime Achievement in Cancer Research Prize Winner Drugging the undruggable: How to finally tackle Myc, Ras, and p53

Year:

Session type:

David Lane
Agency for Science, Technology and Research, Singapore

Bromodomain inhibitors extend the druggable genome: From phenotypic screening to first time in man

Year:

Session type:

Chun-Wa Chung
GlaxoSmithKline, Stevenage, UK

Targeting myeloma cells and their microenvironment

Year:

Session type:

Kenneth C. Anderson
Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

Mechanisms of estrogen receptor transcription in breast cancer

Year:

Session type:

Jason Carroll
Cancer Research UK Cambridge Research Institute, UK

The economics of survivorship

Year:

Session type:

Siobhan McClelland
Macmillan Cancer Support, London, UK

Resistance to PARP inhibition in mouse models of BRCA1-deficient breast cancer

Year:

Session type:

Sven Rottenberg
The Netherlands Cancer Institute, Amsterdam, The Netherlands

Value of information analysis within a stakeholder-driven research prioritization process: An application in cancer genomics

Year:

Session type:

Scott Ramsey
Fred Hutchinson Cancer Research Centre & University of Washington, Seattle, USA

Title TBC

Year:

Session type:

Jeffrey Engelman
Massachusetts General Hospital, USA

The economic burden of cancer across the European Union

Year:

Session type:

Jose Leal
University of Oxford, UK

Introduction: Patients, participants and public – Different perspectives, shared views?

Year:

Session type:

Richard Stephens
NCRI Consumer Liaison Group, UK

Cancer services in England: Providing value for money?

Year:

Session type:

Peter Smith
Imperial College Business School & Centre for Health Policy, London, UK

Cancer research – A positive response from patients

Year:

Session type:

Carolyn Morris
NCRI Consumer Liaison Group, UK

Introduction: Can this patient die comfortably at home?: Knowing the risks and what helps

Year:

Session type:

Barbara Gomes
Cicely Saunders Institute, King’s College London, UK

The National Cancer Patient Experience Survey

Year:

Session type:

Reg Race
Quality Health, UK

Cross-national variations in place of death of cancer patients

Year:

Session type:

Joachim Cohen
Vrije Universiteit Brussel, Brussels, Belgium

From RAGs to riches- Taking public and patient involvement from the high street to the bedside

Year:

Session type:

Ian Lewis
Tenovus, Cardiff, UK

Improving care delivery and personalising care: Integrating ASyMS to cancer care

Year:

Session type:

Nora Kearney
University of Dundee, UK

Introduction: Primary and secondary cancer prevention – lifestyle interventions

Year:

Session type:

Annie Anderson
University of Dundee, UK

Weight management in breast cancer – a primary prevention challenge?

Year:

Session type:

Michelle Harvie
Genesis prevention Centre, University Hospital South Manchester, UK

Lifestyle change in cancer survivors… do we wait for trial evidence?

Year:

Session type:

Wendy Demark-Wahnefried
University of Alabama at Birmingham, Birmingham, USA

The importance of physical activity for cancer survivors: Current evidence and ongoing research.

Year:

Session type:

Johannes Brug
VU University Medical Centre, Amsterdam, The Netherlands

Introduction: Stem cells, heterogeneity and clonal evolution in cancer

Year:

Session type:

Tariq Enver
University College London Cancer Institute, UK

Mechanisms regulating cutaneous cancer stem cells

Year:

Session type:

Cedric Blanpain
Université Libre de Bruxelles & IRIBHM-WELBIO, Brussels, Belgium

Public knowledge and attitudes towards early diagnosis

Year:

Session type:

Jane Wardle
University College London, UK

Title TBC

Year:

Session type:

Peter Dirks
The Hospital for Sick Children, Toronto, Canada

Increasing early detection of symptomatic lung cancer – results of a combined marketing communications campaign and primary care education programme in Leeds, UK

Year:

Session type:

Matthew Callister
Leeds Teaching Hospitals NHS Trust, UK, UK

Clonal evolution and intratumour heterogeneity

Year:

Session type:

Charles Swanton
University College London Cancer Institute, UK

Introduction: Mechanisms of drug resistance

Year:

Session type:

Julian Downward
Cancer Research UK London Research Institute, UK

Introduction: Assessing the economics of cancer care

Year:

Session type:

Peter Smith
Imperial College Business School & Centre for Health Policy, London, UK

Development of an oncology assessment area at the Edinburgh Cancer Centre

Year:

Session type:

Fiona Nussey
NHS Lothian, Edinburgh, UK

Acute oncology – Models of delivery

Year:

Session type:

Brian Haylock
Clatterbridge Cancer Centre, Wirral, UK

Introduction: Predictive biomarker-driven phase II/III trials

Year:

Session type:

Mahesh Parmar
Medical Research Council Clinical Trials Unit, London, UK

COAST-II : Development of a programme for equivalence assessment in IMRT treatment planning.

Year:

Session type:

Rajesh Jena
Cambridge University Hospitals NHS Foundation Trust, UK

The development and validation of predictive biomarkers for Phase II/III Studies

Year:

Session type:

Richard Kennedy
Queen's University, Belfast, UK

Introduction: Advances in the biology and treatment of liver malignancy

Year:

Session type:

John Primrose
University of Southampton & Southampton General Hospital, UK

Predictive biomarker trials in breast cancer

Year:

Session type:

Jo Anne Zujewski
National Cancer Institute, Bethesda, USA

Management of hepatocellular carcinoma

Year:

Session type:

Jean-Francois Dufour
University of Berne, Switzerland

The design of FOCUS 4: a molecularly stratified, multi arm multistaged (MAMS) randomised controlled trial phase II/III programme, in advanced colorectal cancer (ACRC)

Year:

Session type:

Timothy Maughan
Oxford University, UK

Biliary tract cancer: Progress and challenges

Year:

Session type:

John Bridgewater
University College London Cancer Institute, UK

Introduction: Rational approaches to combination of cancer therapies

Year:

Session type:

Ultan McDermott
Wellcome Trust Sanger Institute, Cambridge, UK

Colorectal liver metastases

Year:

Session type:

John Primrose
University of Southampton & Southampton General Hospital, UK

Targeting unique dependencies of RAS mutant tumours by combined pathway inhibition

Year:

Session type:

Julian Downward
Cancer Research UK London Research Institute, UK

Introduction: Cell death, necroptosis and beyond

Year:

Session type:

Henning Walczak
Imperial College London, UK

The application of genetic screens and principles to the design of drug combination strategies for cancer.

Year:

Session type:

Christopher Lord
The Institute of Cancer Research, London, UK

Role of RIPK1 and RIPK3 in cell death modality switches

Year:

Session type:

Peter Vandenabeele
Flanders Institute for Biotechnology (VIB) & Ghent University (UGent), Belgium